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Abstract Recent epidemiological and laboratory-based studies suggest that the anti-diabetic
drug metformin prevents cancer progression. How metformin diminishes tumor growth is not fully 
understood. In this study, we report that in human cancer cells, metformin inhibits mitochondrial 
complex I (NADH dehydrogenase) activity and cellular respiration. Metformin inhibited cellular 
proliferation in the presence of glucose, but induced cell death upon glucose deprivation,  
indicating that cancer cells rely exclusively on glycolysis for survival in the presence of metformin. 
Metformin also reduced hypoxic activation of hypoxia-inducible factor 1 (HIF-1). All of these effects 
of metformin were reversed when the metformin-resistant Saccharomyces cerevisiae NADH 
dehydrogenase NDI1 was overexpressed. In vivo, the administration of metformin to mice 
inhibited the growth of control human cancer cells but not those expressing NDI1. Thus, we have 
demonstrated that metformin's inhibitory effects on cancer progression are cancer cell autonomous 
and depend on its ability to inhibit mitochondrial complex I.
DOI: 10.7554/eLife.02242.001
Introduction
Metformin is widely used to treat patients with type II diabetes mellitus who have high levels of circu-
lating insulin (Nathan et al., 2009). Metformin suppresses liver gluconeogenesis thereby reducing 
glucose release from the liver (Inzucchi et al., 1998; Viollet et al., 2012). In several recent retrospec-
tive studies, investigators have observed an association between metformin use and diminished tumor 
progression in patients suffering from different types of cancers (Evans et al., 2005; Bowker et al., 
2006; Dowling et al., 2012). These data have prompted several prospective clinical trials to deter-
mine the efficacy of metformin as an anti-cancer agent. However, the underlying mechanism by which 
metformin diminishes tumor growth is not fully understood.
There are two postulated mechanisms by which metformin reduces tumor growth. Metformin may 
act at the organismal level, reducing levels of circulating insulin, a known mitogen for cancer cells. 
Alternatively, metformin may act in a cancer cell autonomous manner. Metformin is known to inhibit 
mitochondrial complex I in vitro (Ota et al., 2009; El-Mir et al., 2000; Owen et al., 2000) and it is thus 
possible that this targeting of the electron transport chain could inhibit tumor cell growth (Birsoy 
et al., 2012). This latter hypothesis has been questioned as cancer cells have the ability to survive on 
ATP produced exclusively by glycolysis. Furthermore, cancer cells have been shown to conduct glu-
tamine-dependent reductive carboxylation to generate the TCA cycle intermediates required for cell 
proliferation when the electron transport chain is inhibited (Mullen et al., 2012; Fendt et al., 2013). 
Thus, it is not clear whether inhibition of complex I by metformin would result in decreasing tumor 
growth. In the present study, we directly tested whether inhibition of cancer cell mitochondrial com-
plex I by metformin was required to decrease cell proliferation in vitro and tumor progression in vivo.
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Results
Human HCT116 p53−/− colon cancer cells have previously shown to be sensitive to metformin (Buzzai 
et al., 2007). To determine if metformin treatment inhibited cellular oxygen consumption in these 
cells, we treated HCT116 p53−/− cells with increasing concentrations of metformin in media containing 
the metabolic substrates glucose, pyruvate, and glutamine for 24 hr. Subsequently, we measured cel-
lular oxygen consumption. Metformin inhibited cellular oxygen consumption of HCT 116 p53−/− cells 
at concentrations (0.25–1.0 mM) similar to those reported to affect bioenergetics and gluconeogene-
sis in primary hepatocytes in vitro (Figure 1A; Foretz et al., 2010; Miller et al., 2013).
To determine whether metformin's inhibition of cellular oxygen consumption depended on mito-
chondrial complex I, we stably overexpressed the Saccharomyces cerevisiae protein NDI1 in HCT 116 
p53−/− cells (hereon referred to as NDI1-HCT 116 p53−/− cells). NDI1 is a single-subunit NADH dehy-
drogenase, which oxidizes NADH in a process similar to the multi-subunit mammalian complex I; 
however without proton pumping or ROS generation (Seo et al., 1998). By contrast, mammalian 
complex I contains 45 subunits that pumps protons and generates ROS. NDI1-HCT 116 p53−/− cells 
demonstrated a slight, non-significant elevation in basal cellular oxygen consumption compared to 
control cells and were completely resistant to the effects of metformin on cellular oxygen consumption 
(Figure 1—figure supplement 1, Figure 1B).
To ensure that the inhibition of cellular oxygen consumption by metformin was a direct effect of 
metformin on complex I, we examined mitochondrial respiratory function in saponin-permeabilized 
cells. Saponin removes cholesterol from plasma membranes, allowing the entry of metabolic sub-
strates directly to mitochondria (Jamur and Oliver, 2010). In the presence of ADP and the complex I 
substrates pyruvate and malate, metformin fully inhibited oxygen consumption in permeabilized 
Control-HCT 116 p53−/− cells (Figure 1C). By contrast, metformin had no effect on pyruvate/malate-driven 
oxygen consumption in NDI1-HCT 116 p53−/− cells (Figure 1D). Metformin also had no effect on 
oxygen consumption in saponin-permeabilized cells respiring on the complex II substrate succinate in 
the presence of ADP (Figure 1E). Interestingly, in saponin-permeabilized cells, metformin significantly 
inhibited complex I-dependent respiration at a much lower concentration than that required to inhibit 
oxygen consumption of intact cells, suggesting that transport across the plasma membrane is a barrier 
to metformin's inhibition of complex I. Metformin is known to slowly accumulate in cells in which its 
eLife digest Metformin is widely used to reduce the high blood sugar levels caused by 
diabetes. Recently, several studies have suggested that patients taking metformin who also develop 
cancer have tumors that grow more slowly than average. As clinical trials have already started to 
investigate if metformin is an effective anti-cancer treatment, it is important to understand how it 
might restrict tumor growth.
Researchers have proposed two ways that metformin could affect tumors. First, insulin is known 
to prompt cancer cells to divide, so the slower rate of tumor growth could just be a side-effect of 
the metformin reducing the amount of insulin in the blood. Alternatively, metformin could target 
cancer cells more directly by cutting the energy supply produced by their mitochondria. Metformin 
has been shown to disrupt complex I of the electron transport chain that is used by cells to generate 
energy. However, it is not known if disrupting complex I would actually stop cells dividing because 
they can generate energy in other ways.
Wheaton, Weinberg et al. have now demonstrated that metformin does target complex I in 
cancer cells, and that its effects depend on the amount of glucose available for cells to convert, 
without involving mitochondria, into energy. When there is plenty of glucose, metformin slows 
down the rate at which cancer cells divide, which slows down tumor growth. When the cells are 
deprived of glucose, metformin kills the cells instead.
Metformin also inhibits the pathways that regulate hypoxia inducible factors (HIFs), which are 
part of a system that helps cells to survive low-oxygen conditions, a prominent feature of many 
tumors. This means that metformin may combat cancer more effectively if used alongside other 
treatments that reduce the availability of both oxygen and glucose inside cells. Metformin could 
also potentially treat conditions that are linked to overactive HIFs, such as pulmonary hypertension.
DOI: 10.7554/eLife.02242.002
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Figure 1. Metformin inhibits mitochondrial complex I function. (A) Relative mitochondrial oxygen consumption rate 
(OCR) of intact Control-HCT 116 p53−/− and (B) NDI1-HCT 116 p53−/− cells treated with metformin in complete 
media for 24 hr. (C) Relative complex I (2 mM malate, 10 mM pyruvate, 10 mM ADP)-driven oxygen consumption 
rate of saponin permeabilized Control-HCT 116 p53−/− cells and (D) NDI1-HCT 116 p53−/− cells treated with 
metformin for 20 min in mitochondrial assay buffer. (E) Relative complex II-driven oxygen consumption rate of 
saponin permeabilized Control-HCT 116 p53−/− cells treated with 10 mM succinate and 10 mM ADP in the presence 
of 1 mM metformin or the complex II inhibitor 3-Nitropropionic acid (3-NPA). (F) Representative western blot and 
quantification of levels of OCT1 protein in Control BFP-HCT 116 p53−/− and NDI1-HCT 116 p53−/− cells. Error bars 
are SEM (OCR: n = 4; OCT1: n = 4). * indicate significance p<0.05.
DOI: 10.7554/eLife.02242.003
The following figure supplements are available for figure 1:
Figure supplement 1. NDI1 expression slightly increases oxygen consumption. 
DOI: 10.7554/eLife.02242.004
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uptake is mediated by organic cation transporters (OCTs) (Emami Riedmaier et al., 2013). To ensure 
that NDI1-HCT 116 p53−/− cells are not refractory to metformin because of a change in metformin 
uptake, we analyzed the expression of OCT 1 in both control and NDI1-HCT 116 p53−/− cells. Expression 
of OCT1 protein did not change with the presence of NDI1 (Figure 1F).
We next sought to determine if metformin-dependent inhibition of complex I resulted in changes 
in proliferation and survival of HCT116 p53−/− cells. Metformin did not induce cell death in Control-
HCT 116 p53−/− or NDI1-HCT 116 p53−/− cells in the presence of glucose (Figure 2A,B), however, in the 
absence of glucose, metformin induced cell death in Control-HCT 116 p53−/− but not in NDI1-HCT 116 
p53−/− cells (Figure 2C,D). Metformin diminished cell proliferation in Control-HCT 116 p53−/− cells but 
not in NDI1-HCT 116 p53−/− cells in media containing glucose (Figure 2E,F).
These results indicate that the metformin-dependent inhibition of complex I decreases cell prolifer-
ation in the presence of glucose and increases cell death under glucose deprivation. These inhibitory 
effects of metformin were not specific to HCT116 p53−/− cells as metformin inhibited oxygen consump-
tion and cellular proliferation of Control-HCT 116 p53+/+ cells and Control-A549 human lung cancer 
cells but not NDI1-HCT 116 p53+/+ or NDI1-A549 cells (Figure 2—figure supplement 1 and 2). Taken 
together, these results indicate that the anti-proliferative and cell death promoting effects of met-
formin require mitochondrial complex I inhibition.
We also examined whether phenformin, a more lipophilic biguanide, also exert its anti-proliferative 
effects on cancer cells through inhibition of complex I. Phenformin inhibited oxygen consumption 
in Control-HCT 116 p53−/− cells and saponin-permeabilized Control HCT 116 p53−/− cells at 100-fold 
lower concentration compared to metformin (Figure 3A,C). Expression of NDI1 rescued the phen-
formin-mediated decrease in oxygen consumption (Figure 3B,D). Phenformin diminished cell prolifer-
ation in the control but not NDI1 expressing HCT116 p53−/− cells (Figure 3E,F), and did not induce cell 
death in media containing glucose, similar to metformin (Figure 3G,H). Collectively, these results 
indicate that phenformin also exerts its biological effects through inhibition of mitochondrial complex I.
To determine whether metformin and phenformin diminish proliferation and survival of cells 
lacking endogenous complex I activity, we utilized a variant of CCL16 hamster fibroblasts that harbors 
a mutation in complex I (B2-CCL16) (Seo et al., 1998). Metformin inhibited proliferation of wild-type 
Control-CCL16 hamster fibroblasts but not that of B2-CCL16 cells or of B2-CCL16 cells reconstituted 
with NDI1 (NDI1-CCL16). Metformin and phenformin inhibited cellular oxygen consumption in wild-
type CCL16 but not in CCL16-NDI1 cells (Figure 3—figure supplement 1 and 2). When these cells 
were cultured in galactose-substituted media, both metformin and phenformin induced cell death only 
in wild-type CCL16 cells. Survival of NDI1-CCL16 cells was not affected by metformin or phenformin 
(Figure 3—figure supplements 1 and 2). The B2-CCL16 cells die in galactose in the absence of met-
formin or phenformin since they harbor a mutation in complex I. Taken together, these results con-
firm that the anti-proliferative effects of metformin and phenformin require mitochondrial complex I 
inhibition.
The positive charge of metformin has been proposed to account for it is accumulation within the 
matrix of mitochondria that exhibit a robust inner mitochondria membrane potential (Owen et al., 
2000). Alternatively, the non-polar hydrocarbon-side chain of the drug could promote binding to com-
plexes within mitochondrial membranes. We tested whether the mitochondrial membrane potential is 
necessary for metformin-dependent inhibition of complex I. Saponin-permeabilized Control-HCT 116 
p53−/− cells were induced to respire on pyruvate/malate in the presence of either ADP or CCCP. 
Although both ADP and CCCP induce mitochondrial respiration, only CCCP depolarizes mitochondrial 
inner membrane potential. Metformin inhibited ADP but not CCCP stimulated oxygen consumption 
indicating that the metformin-mediated inhibition of mitochondrial complex I required polarized mito-
chondria (Figure 4A,B). Rotenone, an irreversible inhibitor of complex I, does not require polarized 
mitochondria to inhibit mitochondrial oxygen consumption (Figure 4C,D). Our results suggest that 
metformin would not be effective in suppressing complex I activity of intact cells if mitochondrial inner 
membrane potential was disrupted. Metformin-mediated inhibition of the electron transport chain 
diminishes proton pumping, which might depolarize the mitochondrial membrane, thus limiting accu-
mulation of the drug. However, we did not observe a reduction in the mitochondrial inner membrane 
potential measured using TMRE fluorescent dye in Control and NDI1 HCT116 p53−/− cells after met-
formin treatment (Figure 4E,F). When electron transport function is inhibited, the ATP synthase can 
function in reverse such that it uses ATP generated by glycolysis to pump protons across the inner 
mitochondrial membrane, maintaining membrane potential (Appleby et al., 1999). The ATP synthase 
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Figure 2. Metformin decreases cell proliferation by inhibiting mitochondrial complex I. (A) Percentage of live 
Control-HCT 116 p53−/− or (B) NDI1-HCT 116 p53−/− treated with metformin for 72 hr in media containing 10 mM 
glucose. (C) Percentage of live Control-HCT116 p53−/− or (D) NDI1-HCT 116 p53−/− treated with metformin for 24 hr 
followed by glucose withdrawal for 16 hr. (E) Cell number of Control-HCT 116 p53−/− cells and (F) NDI1-HCT 116 
p53−/− cells 24, 48, and 72 hr post treatment with 0.5 mM or 1 mM metformin in complete media. Error bars are 
SEM (n = 4). * indicates significance p<0.05.
DOI: 10.7554/eLife.02242.005
The following figure supplements are available for figure 2:
Figure supplement 1. Metformin decreases cellular proliferation through inhibition of mitochondrial complex I 
function in HCT 116 p53+/+ cells. 
DOI: 10.7554/eLife.02242.006
Figure supplement 2. Metformin decreases cellular proliferation through inhibition of mitochondrial complex I 
function in A549 cells. 
DOI: 10.7554/eLife.02242.007
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Figure 3. Phenformin decreases cell proliferation by inhibiting mitochondrial complex I. (A) Relative mitochondrial 
oxygen consumption rate (OCR) of intact Control-HCT 116 p53−/− and (B) NDI1-HCT 116 p53−/− cells treated with 
phenformin in complete media for 24 hr. (C) Relative complex I (2 mM malate, 10 mM pyruvate, 10 mM ADP)-driven 
oxygen consumption rate of saponin permeabilized Control-HCT 116 p53−/− cells and (D) NDI1-HCT 116 p53−/− cells 
treated with phenformin for 20 min in mitochondrial assay buffer. (E) Cell number of Control-HCT 116 p53−/− cells 
and (F) NDI1-HCT 116 p53−/− cells 24, 48, and 72 hr post treatment with 0 or 5 µM phenformin in complete media. 
(G) Percentage of live Control-HCT 116 p53−/− or (H) NDI1-HCT 116 p53−/− treated with metformin for 72 hr followed 
in complete media. Error bars are SEM (Relative OCR n = 5; Cell number n = 4). * indicates significance p<0.05.
DOI: 10.7554/eLife.02242.008
Figure 3. Continued on next page
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inhibitor, Oligomycin A, diminished TMRE fluorescence in Control-HCT 116 p53−/− cells treated with 
metformin suggesting that in the presence of metformin, intact cells maintain their mitochondrial 
membrane potential by reversal of the ATP synthase (Figure 4E).
Rotenone irreversibly inhibits complex I, which contributes to its high toxicity in vivo. Because met-
formin is well tolerated, we sought to determine if metformin might reversibly bind to complex I. 
Saponin-permeabilized Control-HCT 116 p53−/− cells were treated with pyruvate and malate to main-
tain the mitochondrial inner membrane potential. Metformin was then added, followed by injection 
of either ADP or CCCP. Metformin inhibited ADP, but not CCCP-stimulated oxygen consumption 
(Figure 5A,B). As metformin accumulation requires mitochondrial membrane polarization (Figure 4A,B), 
these results indicate that metformin reversibly inhibits mitochondrial complex I. If the metformin that 
accumulated in the mitochondrial matrix irreversibly inhibited complex I, then oxygen consumption 
would have remained attenuated in CCCP-treated cells after metformin treatment.
An emerging function of mitochondria distinct from their ability to perform biosynthetic and bio-
energetic reactions is the generation of H2O2, which promotes signaling in normal and cancer cells 
(Hamanaka and Chandel, 2010; Sena and Chandel, 2012). Mitochondrial complexes I and III produce 
superoxide into the mitochondrial matrix, where it is converted quickly to H2O2 by SOD2 (Brand, 
2010). Mitochondrial complex III also generates superoxide into the mitochondrial intermembrane 
space where it escapes through VDACs to cytosol and is converted into H2O2 by SOD1 (Han et al., 
2003; Muller et al., 2004). We measured production and subsequent release of H2O2 from isolated 
mitochondria in the presence of metformin, rotenone, or antimycin A (complex III inhibitor) using pyr-
uvate and malate as substrates.
Consistent with previous reports, rotenone and antimycin increased the release of H2O2 from mito-
chondria isolated from Control-HCT 116 p53−/− cells (Figure 6A,B; St-Pierre et al., 2002; Muller et al., 
2004). In contrast, metformin did not substantially increase H2O2 release, suggesting that metformin 
and rotenone act on different sites of complex I (Figure 6A). When mitochondria were isolated from 
NDI1–HCT 116 p53−/− cells, only antimycin lead to a significant increase in H2O2 release (Figure 6B). 
Previous reports have shown that metformin does not substantially increase H2O2 production in iso-
lated liver mitochondria and that metformin diminishes mitochondrial H2O2 production in response to 
paraquat, which induces mitochondrial ROS production (Batandier et al., 2006; Algire et al., 2012).
One biological consequence of mitochondrial-generated H2O2 is hypoxic stabilization of the 
hypoxia-inducible factors (HIFs) (Chandel et al., 2000). HIFs are involved in metabolic adaptation of 
tumor cells to hypoxia (Semenza, 2012). Metformin reduced hypoxic stabilization of HIF-1α in Control-
HCT 116 p53−/− but not in NDI1-HCT 116 p53−/− (Figure 6C,D). Metformin did not decrease deferox-
amine (DFO) stabilization of HIF-1α protein. DFO is an iron chelator known to directly stabilize HIF-1α 
protein independent of upstream signaling events. Metformin also significantly diminished hypoxic 
activation of HIF-dependent target genes, vascular endothelial growth factor (VEGF), and carbonic 
anhydrase 9 (CA9) in Control-HCT 116 p53−/− but not in NDI1-HCT 116 p53−/− (Figure 6E). Thus, met-
formin is an effective agent to reduce hypoxic activation of HIF-1.
Finally, we directly tested whether tumor cell autonomous inhibition of mitochondrial complex I by 
metformin was required to decrease tumor progression in vivo. As our NDI1-HCT 116 p53−/− cells are 
refractory to multiple effects of metformin in vitro, we reasoned that if metformin acted directly on 
mitochondrial complex I within the tumor cells to reduce tumorigenesis then NDI1-HCT 116 p53−/− 
xenograft tumors would not be inhibited in their growth. However, if metformin acts at the organismal 
level to diminish tumorigenesis then NDI1-HCT 116 p53−/− xenograft tumor growth would be sup-
pressed similar to control tumors. Control-HCT 116 p53−/− cells subcutaneously injected into the left 
flank of nude mice rapidly grew in vivo, while tumors from mice fed metformin through drinking water 
ad libitum starting 4 days post-implantation exhibited a marked reduction in growth (Figure 7A,B). 
NDI1-HCT 116 p53−/− xenograft growth was resistant to metformin therapy (Figure 7A,B), suggesting 
The following figure supplements are available for figure 3:
Figure supplement 1. Metformin inhibits mitochondrial complex I of CCL16 cells. 
DOI: 10.7554/eLife.02242.009
Figure supplement 2. Phenformin inhibits mitochondrial complex I of CCL16 cells. 
DOI: 10.7554/eLife.02242.010
Figure 3. Continued
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that the metformin carries out its tumor inhibitory effects in a cancer cell autonomous manner through 
inhibition of mitochondrial complex I. Importantly, the consumption of water containing metformin 
was similar between control and NDI1 tumor barring mice (Figure 7C). Transcripts for the HIF target 
Figure 4. Metformin inhibition of complex I requires an intact mitochondrial inner membrane potential. (A) 
Complex I (2 mM malate, 10 mM pyruvate)-driven oxygen consumption rate of saponin permeabilized Control-HCT 
116 p53−/− cells over time. At t = 5 min permeabilized cells were treated with either 10 mM ADP to induce respira-
tion with an intact mitochondrial membrane potential or (B) 10 µM CCCP to induce respiration in absence of 
mitochondrial membrane potential. At t = 12 min 1 mM metformin was added to cells. At t = 48 min antimycin A 
was added. (C) Complex I (2 mM malate, 10 mM pyruvate)-driven oxygen consumption rate of saponin-permeabilized 
Control-HCT 116 p53−/− cells. At t = 5 min permeabilized cells were treated with either 10 mM ADP to induce 
respiration with an intact mitochondrial membrane potential or (D) 10 µM CCCP to induce respiration in absence of 
mitochondrial membrane potential. At t = 15 min, 1 μM rotenone was added to cells. At t = 25 min antimycin A was 
added. (E) Mitochondrial membrane potential measured by TMRE staining of Control-HCT116 p53−/− cells or (F) 
NDI1-HCT 116 p53−/− in the presence of 1 mM Metformin, 10 µM CCCP or 2.5 µM Oligomycin A. Error bars are 
SEM (n = 4). * indicates significance p<0.05.
DOI: 10.7554/eLife.02242.011
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genes CA9 and VEGF were diminished in control tumors treated with metformin but not in NDI1 
expressing tumors (Figure 7D,E). The blood glucose, plasma lactate, insulin, and IGF-1 level displayed 
no differences between the metformin-treated animals and control animals at the end of the study 
(Figure 7—figure supplement 1), consistent with previous reports (Tomimoto et al., 2008).
To further bolster our conclusions, we examined tumor growth of A549 cells expressing NDI1 and 
shRNA targeting mammalian NDUFS3, a subunit of the human mitochondrial complex I (Vogel et al., 
2007). A549 cells are null for the tumor suppressor LKB1 and are known to be responsive to metformin 
therapy (Rocha et al., 2011). Furthermore, LKB1-deficient tumors are more susceptible to the related 
biguanide phenformin (Shackelford et al., 2013). We replaced the endogenous mitochondrial 
complex I by expressing the NDI1 protein in A549 cells stably expressing shRNA against NDUFS3 
(Figure 7—figure supplement 2A), referred to as NDI1-shNDUFS3-A549 cells. The Control-A549 cells 
contain the empty vectors with selection markers BFP and puromycin for NDI1 and shRNA, respec-
tively. NDI1-NDUFS3-A549 cells were resistant to the metformin-mediated reduction in cellular and 
mitochondrial oxygen consumption and cell proliferation (Figure 7—figure supplement 2B–G). 
Metformin also decreased HIF-1a protein levels in control but not in NDI1-NDUFS3-A549 cells 
(Figure 7—figure supplement 3A). Control-A549 cells subcutaneously injected into the left flank of 
nude mice rapidly grew in vivo, while tumors from mice fed metformin through drinking water ad 
libitum starting 2 weeks prior to tumor induction exhibited a marked reduction in growth over 45 days 
(Figure 7—figure supplement 3B). By contrast, NDI1-NDUFS3-A549 xenografts were completely 
resistant to metformin therapy, suggesting that metformin carries out its tumor inhibitory effects in a 
cell autonomous manner through inhibition of mitochondrial complex I in these cells (Figure 7—figure 
supplement 3C). NDI1-NDUFS3-A549 xenografts grew slower than control xenografts in untreated 
mice. An alternative explanation for the resistance of NDI1-NDUFS3-A549 cells to metformin could be 
that effects of metformin are blunted in slower-growing cells. However, based on our results from 
HCT116 cells in vivo and extensive analysis of A549 cells in vitro, we find that it is likely that NDI1 
expressing A549 cells are also resistant to metformin in vivo due to rescue of complex I activity by the 
NDI1 protein.
Discussion
The mechanisms by which metformin inhibits cancer growth is not fully understood. Metformin has 
been previously shown to inhibit mitochondrial complex I, yet it is not known whether metformin 
exhibits its anti-tumor effects through inhibition of complex I. It is important to note that many 
Figure 5. Metformin reversibly inhibits mitochondrial complex I. (A) Complex I (2 mM malate, 10 mM pyruvate)-driven 
oxygen consumption rate of saponin permeabilized Control-HCT 116 p53−/− cells over time. At t = 5 min 
permeabilized cells were exposed to 1 mM metformin. At t = 25 min respiration was stimulated with either 10 mM 
ADP to induce respiration with an intact mitochondrial membrane potential or (B) 10 µM CCCP to induce respira-
tion lacking membrane potential with 10 mM ADP. At t = 42 min antimycin A was added. For mitochondrial 
membrane potential error bars are SEM (n = 4). For oxygen consumption rates, error bars are standard deviation  
(n = 6). * indicates significance p<0.05.
DOI: 10.7554/eLife.02242.012
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Figure 6. Metformin reduces HIF-1 activation through inhibition of mitochondrial complex I. (A and B) H2O2 levels emitted by mitochondria isolated from 
Control-HCT 116 p53−/− and NDI1-HCT 116 p53−/− cells respiring on 2 mM malate and 10 mM pyruvate. Mitochondria were treated with 1 mM Metformin, 
500 nM rotenone, 500 nM Antimycin, or left untreated. H2O2 levels were measured using Amplex Red. (C) Levels of HIF1α protein in Control-HCT 116 
Figure 6. Continued on next page
Human biology and medicine
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commonly utilized drugs have been shown to inhibit mitochondrial function in vitro; however, for many 
of these drugs it is not clear whether the in vivo mechanism of action is through modulating mitochon-
drial metabolism (Gohil et al., 2010). In the present study, we genetically demonstrate that metformin 
acts as a complex I inhibitor in vitro and in vivo to inhibit tumorigenesis. Our current findings bolster 
our previous findings highlighting the importance of mitochondrial metabolism as essential for cancer 
proliferation (Weinberg et al., 2010; Sullivan et al., 2013). Our results are consistent with a recent 
report demonstrating another biguanide phenformin exerts its anti-tumor effects by inhibiting com-
plex I (Birsoy et al., 2014). However, unlike metformin, phenformin has been discontinued because of 
frequent occurrence of lactic acidosis (Bailey and Turner, 1996). While our study highlights the impor-
tance of mitochondrial complex I inhibition within cancer cells as a major mechanism by which met-
formin reduces tumor burden, it does not necessarily preclude any additional organismal effects of 
metformin that might reduce tumor progression in certain cancers. Specifically, cancer cells that 
express insulin receptors might be affected by metformin's inhibition on hepatic gluconeogenesis to 
reduce circulating insulin levels (Goodwin et al., 2012).
The levels of metformin within cells is regulated by a balance between uptake mechanisms, which 
are dependent on expression of organic cation transporters (OCT 1, 2, and 3), and expulsion mecha-
nisms, which are dependent on expression on multidrug and toxin extrusion proteins (MATE1 and 
MATE 2) (Emami Riedmaier et al., 2013). Cancer cells are likely to have a wide range in expression 
of uptake and extrusion proteins allowing for metformin accumulation. The uptake of metformin in 
mitochondria is also dependent on mitochondrial membrane potential. Metformin exists as a cation at 
physiological pH and thus its accumulation within mitochondria is predicted to increase as a function 
of the mitochondrial membrane potential. The inhibition of electron transport at complex I by met-
formin should reduce the mitochondrial membrane potential as proton pumping is linked to elec-
tron transport. However, we observed that metformin-treated cells maintain their mitochondrial 
membrane potential in part due to the reversal of the ATP synthase thus allowing accumulation of 
metformin in the mitochondrial matrix (Figure 3). It is well known that cells with compromised ETC 
can sustain mitochondrial membrane potential through this mechanism (Appleby et al., 1999). 
Collectively, our results indicate that will inhibit mitochondrial complex I and decrease tumorigenesis 
in cancer cells that have transporters across the plasma membrane, as well as a robust inner mitochon-
drial membrane potential to allow metformin to reach the mitochondrial matrix. It will be of interest 
to observe whether metformin's efficacy as an anti-cancer agent is dependent on the tumor expres-
sion of OCTs.
Our study also reveals that metformin's inhibition on mitochondrial complex I is distinct from the 
classical complex I inhibitor rotenone. Metformin requires a robust mitochondrial membrane potential 
to accumulate in the mitochondrial matrix and reversibly inhibits complex I. By contrast, rotenone is an 
irreversible inhibitor of complex I that does not require mitochondrial membrane potential. Rotenone 
accumulation is not dependent on specific transporters expressed in the plasma membrane and readily 
accumulates in all cells and thus is highly toxic. Furthermore, metformin does not promote generation 
of ROS from complex I, while rotenone stimulates ROS production from complex I (Figure 5A). The 
flavin site within Complex I produces ROS and previous studies indicate that rotenone inhibits com-
plex I downstream of the flavin site, stimulating ROS generation (Pryde and Hirst, 2011; St-Pierre 
et al., 2002). It is likely that metformin acts upstream of this site, inhibiting complex I activity while 
also inhibiting ROS generation. Mitochondrial complex III also produces ROS (Muller et al., 2004). 
Therefore, metformin by inhibiting the complex I would limit electron flow to complex III thereby 
reducing ROS generation from complex III. A consequence of mitochondrial complex III ROS genera-
tion is the hypoxic activation of HIF-1 (Bell et al., 2007). Indeed, we found that metformin reduced 
hypoxic stabilization of HIF-1α protein and HIF-dependent target genes. This result is consistent with 
our previous study in which we identified multiple mitochondrial inhibitors in a large-scale chemical 
p53−/− and NDI1-HCT 116 p53−/− cells treated with 0 or 1 mM metformin for 24 hr, then placed in normoxia (21% O2), hypoxia (1.5% O2) or treated with 
Deferoxamine (DFO) for 8 hr. (D) Quantification of HIF1α protein levels from panel C. (E) Hypoxic-induced expression of HIF target genes in Control-HCT 
116 p53−/− and NDI1-HCT 116 p53−/− treated with 0, 0.5 mM or 1 mM metformin for 24 hr following treatment with normoxia or hypoxia for 16 hr. Error bars 
are SEM (n = 3 for Amplex Red; Blot is representative of four independent blots quantified in D, n = 4 for gene expression). * indicates significance p<0.05.
DOI: 10.7554/eLife.02242.013
Figure 6. Continued
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Figure 7. Metformin inhibits mitochondrial complex I to diminish tumor growth. (A) Average tumor volume in mice 
injected with 3 × 106 Control-HCT 116 p53−/− or NDI1-HCT 116 p53−/− cells injected into the left flank of J:Nu mice. 
Mice were given ad libitum, water free of metformin (squares) or were treated with 250 mg/kg of metformin in the 
drinking water starting 4 days post tumor injection (triangles). (B) Average tumor mass from mice injected with 
3 × 106 Control-HCT 116 p53−/− or NDI1-HCT 116 p53−/− cells injected into the left flank of J:Nu mice after 32 days. 
(C) Average daily water consumption of mice treated with metformin (1.25 mg/ml). (D) HIF target genes expression 
measured in Control-HCT 116 p53−/− or NDI1-HCT 116 p53−/− tumors treated with metformin. Error bars are SEM  
(n = 8 per group for tumor study, n = 8 for H2O consumption, error bars represent standard deviation of two cages 
with four mice house in each cage, n = 3 for gene expression). * indicates significance p<0.05.
DOI: 10.7554/eLife.02242.014
The following figure supplements are available for figure 7:
Figure supplement 1. Metformin treatment of tumor bearing mice does not alter blood glucose, plasma lactate, 
IGF-1, and insulin levels. 
DOI: 10.7554/eLife.02242.015
Figure 7. Continued on next page
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screen for inhibitors of hypoxic activation of HIF (Lin et al., 2008). Beyond cancer, metformin might be 
an effective treatment for diseases associated with hyperactivation of HIF such as pulmonary hyperten-
sion (Shimoda and Semenza, 2011). The concentration of metformin we administered to mice in this 
report is predicted to achieve plasma concentrations of metformin similar to those in humans receiving 
metformin therapy. In our study, metformin was administered to drinking water at a concentration of 
1.25 mg/ml, approximately 250 mg/kg. Conversion of doses from mice to human is achieved using a 
formula based on body surface area normalization (Reagan-Shaw et al., 2008). The human equivalent 
dose of 250 mg/kg metformin in mice is 20.27 mg/kg or 1418 mg for a 70 kg adult. Patients typically 
receive 500–2500 mg metformin per day (Scarpello and Howlett, 2008). In these patients receiving 
metformin therapy, plasma levels range between 0.5–2 µg/ml; approximately 4 µM–15 µM (Graham 
et al., 2011). Previous studies have shown that mice receiving drinking water containing 1–5 mg/ml of 
metformin have a plasma steady-state metformin concentration of 0.45–1.7 µg/ml (Memmott et al., 
2010), indicating that our metformin dosage falls within a clinically relevant range.
Metformin concentrations (250–1000 µM) used for in vitro experiments in this report are in the range 
utilized by investigators in the diabetes field to examine the effects of metformin on primary murine and 
human hepatocytes (Foretz et al., 2010; Stephenne et al., 2011; Miller et al., 2013). A perplexing 
observation revealed in our study and previous studies is that the metformin concentrations required 
to induce biological effects in vitro are a magnitude of order higher than plasma level concentrations 
of metformin in vivo. A likely cause for this difference is the accumulation of metformin in liver or 
tumors to local concentrations that are much higher than in the circulating plasma. Indeed, the gut has 
been shown to accumulate metformin in the mM range (Bailey et al., 2008; Proctor et al., 2008).
In summary, our results indicate that metformin reversibly inhibits mitochondrial complex I within 
cancer cells to reduce tumorigenesis. Metformin inhibits tumorigenesis through multiple mechanisms 
including the induction of cancer cell death in conditions, when glucose is limited and through inhibi-
tion of mitochondrial ROS-dependent signaling pathways that promote tumorigenesis (i.e., HIF). 
These results indicate that metformin would be most effective in low glucose and oxygen conditions. 
It will be of interest to determine whether metformin treatment might provide a useful adjunct to 
therapies that limit glucose uptake (e.g., PI3K inhibitors) or drive tumors to low glucose and oxygen 
levels (e.g., anti-angiogenic inhibitors).
Materials and methods
Generation of cell lines and culture
NDI1 (+NDI1) and control pWPI vectors containing BFP (+BFP) were transfected into 293FT cells using 
lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) along with pMD2.G and psPAX2 packaging 
vectors to produce Control-BFP or NDI-BFP lentivirus. Control-HCT116 p53−/−, NDI1-HCT 116 p53−/−, 
Control-A549, and NDI1-A549 were created by infecting parental HCT116 p53−/− or A549s with either 
Control-BFP lentivirus or NDI1-BFP lentivirus. Selection of the BFP expressing Control-HCT116 p53−/−, 
NDI1-HCT 116 p53−/−, Control-A549, and NDI1-A549 was done by periodic fluorescence-activated cell 
sorting (FACS) for BFP-positive cells with a MoFlo (Beckman–Coulter, Brea, CA, USA). Control-HCT 
116 p53−/−, NDI1-HCT 116 p53−/−, Control-HCT116 p53+/+, NDI1-HCT 116 p53+/+, Control-A549, 
NDI1-A549 cells, NDI1-NDUFS3-A549, CCL16, CCL16-B2, and CCL16-NDI1 were cultured in DMEM 
supplemented with 10% fetal bovine serum, 1% HEPES, and 1% penicillin-streptomycin. Cells were 
routinely checked for BFP expression using FACS to ensure high NDI1 expression. TRC consortium 
validated pLKO.1 shRNA clones against control or NDUFS3 were obtained from Sigma and the len-
tivirus was produced in COS1 cells (TRCN0000218593). Control-A549 and NDI1-A549 cells infected 
the pLKO.1 lentivirus were additionally selected under continuous puromycin selection (1 μg/ml).
Figure supplement 2. Metformin inhibits cellular proliferation and pro- proliferative signaling via complex I 
inhibition. 
DOI: 10.7554/eLife.02242.016
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Proliferation and cell viability
1.5 × 105 HCT 116 wild-type or p53 null cells (1 × 105 A549 and CCL16 cells) were plated on 35-mm 
dishes. At 24, 48, and 72 hr after plating, cells were trypsinized and counted using a Vi-Cell (Beckman–
Coulter, Brea, CA, USA). Cell viability percentage was determined by trypan blue exclusion after 24 hr of 
treatment with metformin in DMEM with 10% dialyzed fetal bovine serum, 1% HEPES and 1% penicillin-
streptomycin and lacking glucose (HCT 116) or with galactose substituted for glucose (CCL16).
Oxygen consumption rate measurements
Oxygen consumption rates (OCR) were measured utilizing the XF24 Seahorse Biosciences Extracellular 
Flux Analyzer. 2 × 104 HCT 116 s (1.5 × 104 A549 and CCL16 cells) were plated in the seahorse cell 
plate and incubated overnight. HCT 116 cells were then incubated for 24 hr in metformin hydrochlo-
ride (Sigma-Aldrich, St. Louis, CA, USA). 30 min before assay, the media were changed to 500 μl of 
fresh media containing metformin. For A549 and CCL16 cells, metformin was injected onto the cells 
using the Flux Analyzer and OCR was measured following a 20-min incubation. Basal mitochondrial 
oxygen consumption rate was determined by subtracting the antimycin A (Sigma, 1 μM) sensitive OCR 
from the basal OCR following normalization for cell number. The coupled mitochondrial oxygen con-
sumption rate was determined by subtracting the mitochondrial respiration following Oligomycin A 
(Sigma) treatment from the basal mitochondrial oxygen consumption rate. The complex I and complex 
II specific contributions to oxygen consumption were measured by changing 5 × 104 HCT 116 cells 
(2 × 104 A549 cells) plated overnight in complete DMEM into mitochondrial assay buffer (70 mM 
sucrose, 220 mM mannitol, 10 mM KH2PO4, 5 mM MgCl2, 2 mM HEPES, 1.0 mM EGTA, and 0.2% 
(wt/vol) fatty-acid free BSA, pH 7.2), supplemented with 10 mM ADP (Sigma) and permeabilized by 
saponin injection (120 μg/ml, Sigma). The OCR was observed after saponin injection for loss of O2 
usage until stabilization at baseline where intracellular substrates have diffused out of the permeabi-
lized cells. The complex I substrates (pyruvate 10 mM, malate 2 mM) or the complex II substrate (suc-
cinate 10 mM) was then added and the increase in OCR was measured. For complex II OCR, rotenone 
(Sigma, 1 μM) was added to inhibit complex I oxygen consumption. Post-injection of mitochondrial 
substrates, metformin was added and the OCR was measured. Complex I or II OCR was determined 
as the difference between substrate-free and substrate-added OCR. To examine whether mitochon-
drial inhibitors depend on membrane potential to inhibit complex I, cells were treated with saponin 
(120 μg/ml) and the complex I substrates (pyruvate 10 mM, malate 2 mM). Next, the cells were treated 
with either Carbonyl cyanide m-chlorophenyl hydrazone (CCCP, Sigma −10 μM) or ADP (10 mM) to 
induce respiration. The complex I inhibitors metformin (1 mM) or rotenone (1 μM) were then added to 
assay inhibitory capacity in the presence or absence of membrane potential. Finally, the cells were 
treated with antimycin (1 μM) to completely inhibit mitochondrial oxygen consumption. To determine 
the reversibility of metformin inhibition of complex I, cells were permeabilized with saponin and con-
currently treated with complex I substrates (pyruvate 10 mM, malate 2 mM). The cells were then 
treated with 0 or 1 mM metformin for 20 min. Next, the cells were treated with CCCP (10 μM) or ADP 
(10 mM) to induce respiration in the presence or absence of mitochondrial membrane potential. 
Finally, the cells were treated with antimycin A (1 μM).
Mitochondrial membrane potential measurements
1 × 106 Control-HCT 116 p53−/− or NDI1-HCT 116 p53−/− cells were plated in 35-mm dishes in complete 
media and incubated overnight. The next day the cells were switched to media containing metformin 
and incubated for an additional 24 hr. After 24 hr, 50 nM tetramethylrhodamine (TMRE, Life Technologies) 
was added to the media for 30 min. The cells were washed, isolated, and resuspended in 1 ml of PBS. 
10 μM CCCP, 2.5 μM Oligomycin A or no treatment was added and cells were incubated for an additional 
30 min. The cells were then analyzed on BD LSRFortessa (San Jose, CA, USA) machine. The cells were 
gated for singlets and then the mean TMRE fluorescence was obtained using FlowJo analysis software.
ROS measurements
The cells were scraped into mitochondrial isolation buffer (250 mM Sucrose, 1 mM EGTA, 20 mM Tris 
pH 7.4) and disrupted by 10 strokes with a Dounce homogenizer and 5 expulsions through a 28-gauge 
needle. The lysates were centrifuged at 500×g for 10 min to remove nuclei, followed by centrifugation 
at 18,000×g for 20 min to pellet mitochondria. Mitochondrial fractions were suspended in a reaction 
buffer containing 120 mM KCl, 5 mM KH2PO4, 3 mM HEPES, 1 mM EGTA, and 0.3% BSA, pH 7.2. 
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Mitochondria respired on 2.5 mM pyruvate and 1 mM malate in the presence or absence of 500 nm 
Antimycin A or 1 mM Metformin. Superoxide dismutase (200 U/ml; Sigma) was used to convert mito-
chondria-produced superoxide to hydrogen peroxide (H2O2). In the presence of horseradish peroxi-
dase (10 U/ml, Thermo Scientific), Amplex Red (100 µM, Molecular Probes) reacts with H2O2, producing 
the fluorescent oxidation product, resorufin. Fluorescence was measured at excitation 544 nm, emis-
sion 590 nm.
Immunoblot analysis
Protein was extracted using cell lysis buffer (Cell Signaling, Danvers, MA, USA) plus PMSF (600 μM). 
Protein concentration was quantified using the BCA Protein Assay (Pierce, Rockford, IL, USA). Protein 
samples were resolved on SDS polyacrylamide gels (Bio-Rad) and subsequently transferred to nitrocel-
lulose membranes by semi-dry transfer using the Trans-Blot Turbo (Bio-Rad). To determine levels of 
HIF1α (BD Transduction Laboratories, Clone 54/HIF-1a) protein levels, HCT 116 cells were pretreated 
with 1 mM metformin or left untreated for 24 hr followed by treatment with 100 µM DFO, or incuba-
tion in 1.5% O2 for 8 hr. For A549s, cells were pretreated with 2 mM metformin or mock treatment for 
1 hr and treated with mock treatment, 100 μM DFO, or incubated in a hypoxia chamber at 1.5% O2 for 
4 hr. OCT1 (Novus Biologicals, Littleton, CO, USA) and NDUFS3 (MitoSciences) protein expression 
were assessed using the same technique above without any treatment conditions. α-tubulin (Sigma) 
was used as a loading control for protein blots assessing HIF1a and NDUFS3 protein levels while 
β-actin (Sigma) was used as a control for OCT1 protein quantification. Image Studio Lite version 3.1 
(Licor) was used for analysis and quantification of protein levels. In brief, blots were scanned at high 
resolution and imported into Image Studio. Individual lanes of HIF1α and OCT1 protein levels were 
normalized to tubulin and actin respectively. Relative levels of HIF1a were normalized to an untreated 
sample incubated at 21% O2.
Real time PCR of HIF target genes
1.5 × 105 Control-HCT 116 p53−/− or NDI1-HCT 116 p53−/− cells were plated on 24-well plates in com-
plete media and 24 hr later treated with media without serum and metformin for 24 hr. Fresh media 
with or without metformin were added just before cells were exposed to either normoxia (21% O2) or 
hypoxia (1.5% O2) for 16 hr. Cells were washed once with ice-cold PBS and RNA was extracted using 
commercial kit (Aurum Total RNA mini Kit, Bio-Rad Hercules, CA). 1 µg of RNA was transcribed to 
cDNA using the iScript cDNA synthesis kit (Bio-Rad) and the relative concentrations of cDNA were 
analyzed by qPCR on a Bio-Rad CFX384 Touch Real-Time PCR Detection System using iQ SYBR Green 
Supermix (Bio-Rad) and the following primer sequences: CA9 sense: CCGAGCGACGCAGCCTTTGA 
CA9 antisense: GGCTCCAGTCTCGGCTACCT VEGF sense: TACCTCCACCATGCCAAGTG VEGF 
antisense: GATGATTCTGCCCTCCTCCTT 18s sense: CGTTGATTAAGTCCCTGC CCTT 18s antisense: 
TCAAGTTCGACCGTCTTCTCAG. HIF target gene expression was analyzed from tumor RNA isolated 
using TRIzol (Life Technologies, Grand Island, NY, USA). RNA was isolated and immediately tran-
scribed to cDNA using the iScript cDNA synthesis kit, and the relative concentrations of cDNA were 
analyzed as described above.
Blood glucose levels and ELISA assays
Blood was extracted weekly from female outbread athymic nude mice (J:Nu, Jackson Labs). The mice 
were injected with 1 × 106 A549 cells and treated with either water free of metformin or water contain-
ing 250 mg/kg metformin. Blood glucose levels were determined weekly using a glucometer (One 
Touch). Blood was collected into heparinized tubes at the end of the xenographic tumor study 
described below. Plasma was then isolated from whole blood by spinning at 21,000 × g for 5 min. 
IGF-1 levels were determined using an ELISA (Abcam, Cambridge, MA, USA), as were insulin levels 
(Millipore, Billerica, MA, USA). Finally, lactate levels were measured using a colorimetric kit (Abcam).
Mouse xenograft studies
Female J:Nu mice were injected with 3 × 106 Control-HCT 116 p53−/− or NDI1-HCT 116 p53−/− using a 
27-gauge needle. 4 days post-injection mice were treated with water supplemented with metformin 
(Sigma) or water alone and fluid intake was monitored daily to ensure an effective dose of 1.25 mg/ml or 
250 mg/kg (Buzzai et al., 2007) of metformin. In mice receiving drinking water containing 1–5 mg/ml 
of metformin, the plasma steady-state metformin concentration is reported to be in the range of 
0.45–1.7 µg/ml (Memmott et al., 2010). In patients receiving metformin therapy, plasma levels are 
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between 0.5 µg/ml and 2 µg/ml (Graham et al., 2011). This treatment created four experimental 
groups: Control-HCT 116 p53−/− with H2O (n = 8), Control-HCT 116 p53−/− with Metformin (n = 8), 
NDI1-HCT 116 p53−/− with H2O (n = 8), NDI1-HCT 116 p53−/− with Metformin (n = 8). Experiments are 
from two independent cohorts of four mice each. Tumors were measured three times per week using 
calipers and tumor volume was determined using the equation (3.14/6 × L × W2). At the completion of 
the study, mice were euthanized and the tumors were extracted and weighed. For A549s, 3 × 106 
Control-A549 or NDI1-NDUFS3-A549 cells were injected into the left flank of female nude mice 
(Nu:Nu) administered metformin (250 mg/kg) in their drinking water for 2 weeks prior to cell injection 
and continuously administered throughout the experiment. All mouse work was done in accordance 
with Northwestern University Institutional Animal Care and Use Committee.
Statistical analysis
Data are presented as the mean ± SEM. Statistical significance was determined using 1-way ANOVA 
with a Bonferroni posttest correction, 2-way ANOVA when two variables were present, or the students 
t test comparing control to experimental conditions for p<0.05. For all differences uncovered, a stu-
dent t test was performed to verify differences between control and experimental groups.
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